IMMUNOGEN

ImmunoGen, Inc. Investor Relations Department 830 Winter Street Waltham, MA 02451 United States

Visit IR website Sign-up for Email alerts

NASDAQ: IMGN	
Last Trade:	6.57
Trade Time:	1:00 PM ET Sep 19, 2017
Change:	-0.19 🖶 (-2.811%)
Day Range	6.52 - 6.82
52-Week Range	1.51 - 8.84
Volume	1,313,372

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinicalstage biotechnology company that develops targeted cancer therapeutics using its proprietary antibodydrug conjugate (ADC) technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRαpositive platinumresistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlierstage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla¹, in other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, B... (more)

Stock Performance



Press Releases [View all]

Sep 5, 2017

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

Sep 1, 2017

ImmunoGen Announces Agreements to Exchange \$76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock

Aug 29, 2017

Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate **Products**

Aug 1, 2017

ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity **Growth Conference**

Jul 28, 2017

ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results

Upcoming Events [View all]

Sep 25, 2017 3:35 PM ET Cantor Fitzgerald 2017 Global Healthcare Conference

Financials [View all]

Second Quarter Financial Results

Aug 25, 2016 Annual Report (10-K)

Apr 28, 2017 Proxy Statement (DEF 14A)

Aug 4, 2017 Quarterly Report (10-Q)

May 5, 2017 Quarterly Report (10-Q)

Nov 4, 2016

Quarterly Report (10-Q)